Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The FTC’s noncompete ban could force sweeping changes in the health care industry, but implementation of the rule will almost certainly be held up by…
APCCC 2024, alternative PSMA Ligands, 68Ga-PSMA-11, 18F-DCFPyL, 18F-PSMArh7.3, 18F-PSMA-1007, benign bone uptake, PSMA-617, PSMA-I&T, SPOTLIGHT trial, 18F-PSMArh7.33, UCLA/UCSF trial, CONDOR trial.
APCCC 2024, metastatic castration resistant prostate cancer (mCRPC), PSMA radioligand therapy, Docetaxel, cabazitaxel, 177Lu-PSMA-617, TROPIC trial, CARD trial, TAX327 trial, SWOG 9916 trial, PRESIDE trial,…
The NIH will raise the minimum salary for postdocs to $61,008, responding to calls from young life scientists to provide a living wage.
At the 2024 UCSF-UCLA PSMA Conference, Oliver Sartor advocates for the early use of PSMA radioligand therapy in prostate cancer treatment, challenging the traditional reliance…
Were you unable to attend APCCC 2024? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.
APCCC 2024, prostate cancer, Lancet Commission on Prostate Cancer, prostate cancer population, worldwide prostate cancer cases, prostate cancer future outlook, global prostate cancer disparity.
Scientists at Scripps Research have developed atomic-level structural models of enzymes linked to autoimmune and inflammatory conditions, such as lupus and Alzheimer’s disease. When nucleic…
Congress did nothing this spring to rein in how pharmacy benefit managers operate, and the PBM industry spent big to get that result, new disclosures…
APCCC 2024, prostate cancer, PARP Inhibitors, Side Effects of PARP Inhibitors, PARP inhibitor monotherapy trials, MAGNITUDE trial, PROpel trial, TALAPRO-2 trial, PARP inhibitor hematological side…